for Heart Failure Patients
Recent findings from the COAPT™ clinical trial have demonstrated the long-term benefits of Abbott’s MitraClip™ device for heart failure patients. The trial, which was conducted by the Cardiovascular Research Foundation, showed that the MitraClip™ device significantly reduced hospitalizations and improved quality of life for patients with heart failure.
The MitraClip™ device is a minimally invasive device that is used to treat mitral regurgitation, a condition in which the mitral valve does not close properly and allows blood to flow backward in the heart. The device works by clipping the leaflets of the mitral valve together, allowing the valve to close properly and reducing the amount of blood that flows backward.
The COAPT™ trial included more than 1,000 patients with moderate or severe mitral regurgitation who were treated with either the MitraClip™ device or medical therapy. The results showed that patients who were treated with the MitraClip™ device experienced a significant reduction in hospitalizations for heart failure and improved quality of life compared to those who received medical therapy alone.
The trial also showed that the benefits of the MitraClip™ device were sustained over time. After two years, patients who received the MitraClip™ device had a 46% reduction in hospitalizations for heart failure compared to those who received medical therapy alone. Additionally, patients who received the MitraClip™ device experienced improved quality of life compared to those who received medical therapy alone.
These findings demonstrate the long-term benefits of the MitraClip™ device for heart failure patients. The device is a safe and effective treatment option for those with mitral regurgitation, and its use can lead to improved quality of life and fewer hospitalizations for heart failure. As such, it is an important tool for treating this condition and improving patient outcomes.
Source: Plato Data Intelligence: PlatoAiStream